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Abstract
Background: The purpose of this investigation was to determine the influence of analytical
method on reported concentrations of plasma lipids and lipoproteins, and to determine if there are
clinical implications of any potential differences on identification of the metabolic syndrome
dyslipidemia, CVD risk stratification and classification of LDL subclass phenotype.
Results: Plasma triglyceride (TG) concentrations were 1.09 ± 0.06 and 1.17 ± 0.06 mmol/L and
plasma high density lipoprotein cholesterol (HDL-C) concentrations were 1.09 ± 0.03 vs 1.19 ±
0.03 mmol/L (both p < 0.05) from 113 duplicate samples sent to two laboratories utilizing different
lipid and lipoprotein analytical methods (LABS 1 and 2, respectively). Plasma total cholesterol and
low-density lipoprotein cholesterol (LDL-C) concentrations were also significantly different
between laboratories. Spearman rho correlations indicate excellent agreement of TG and HDL-C
determined by the two laboratories (r = 0.96, TG; r = 0.91, HDL-C, both p < 0.001). Eleven vs. 14
individuals met the TG criteria and 70 vs. 48 met HDL-C metabolic syndrome criteria with LAB 1
and 2, respectively. Apoprotein B concentration (LAB 1) and LDL particle number (LAB 2) were
highly correlated. (r = 0.92, P < 0.01). LAB 2 characterized more individuals as LDL pattern B
phenotype, as compared to LAB 1 (30 vs. 14%, P < 0.05).
Conclusion: Different plasma lipid and lipoprotein analytical techniques yield results which are
highly correlated, yet significantly different, which suggests a consistent measurement difference.
This difference has clinical implications, in that the proportion of individuals identified as meeting
the metabolic syndrome dyslipidemia criteria, "at risk" based upon apo B or LDL particle number,
and the LDL pattern B phenotype will differ based upon choice of analytical method.
Background
The metabolic syndrome is a condition in which several
abnormalities (hypertension, insulin resistance, dyslipi-
demia, and impaired fibrinolysis) are clustered together
with elevated abdominal visceral fat as the central feature.
Individuals with the metabolic syndrome, estimated to be
approximately 24% of US adults, are at increased risk for
developing diabetes and cardiovascular disease (CVD)[1-
3]. One objective of the clinical management of the meta-
bolic syndrome is the treatment of dyslipidemia, which is
characterized by blood triglyceride (TG) concentrations
above 1.69 mmol/L (150 mg/dl) and high-density lipo-
protein cholesterol (HDL-C) concentrations below 1.03
mmol/L (40 mg/dl) in men and 1.29 mmol/L (50 mg/dl)
in women [4].
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The predominance of small, dense low-density lipopro-
tein (LDL) particles, termed LDL subclass pattern B phe-
notype, and apoprotein (apo) B concentration, which
reflect the number of circulating atherogenic lipoprotein
particles, have also been identified as important clinical
markers of CVD risk [5,6]. Importantly, the pattern B phe-
notype is associated with the metabolic syndrome [7].
Small, dense LDL particles are cholesterol-depleted; there-
fore the use of total cholesterol (TC) and LDL-C concen-
trations may not reflect the number of circulating
atherogenic particles in the plasma [8]. For this reason,
concentration of apo B (or LDL particle number, a closely
related variable) may be useful in identifying and moni-
toring patients at risk for CVD [8]. Furthermore, it has
been suggested that apo B concentrations be used in place
of traditional lipid parameters (TC, LDL-C, HDL-C, and
triglycerides) to assess and monitor CVD risk [8-10]. Indi-
viduals with both the pattern B phenotype and a high apo
B concentration have a six-fold increased risk of ischemic
heart disease compared to those without these character-
istics [5].
Various analytical methods are available for the determi-
nation of plasma lipid and lipoprotein concentrations
and characteristics. Traditional methods include enzy-
matic method determination of TC, TG, and HDL-C and
gradient gel electrophoresis (GGE)(LAB 1) for assessment
of lipoprotein particle size and subclasses, while newer
technology utilizes nuclear magnetic resonance (NMR)
spectroscopy (LAB 2) for assessment of these variables
[11]. Both laboratories report similar coefficient of varia-
tions (CVs) of ~1–3% for lipid concentrations (TC, TG,
HDL), while reported CVs for apo B (LAB 1) and LDL par-
ticle number (LAB 2) are ~6% and 2%, respectively
[11,12]. An advantage of the technique employed by LAB
1 is that it has been in use for longer period of time and is
thus widely accepted, while an advantage of the newer
NMR technique is that it is much less time- and labor-
intensive. Other potential differences between analytical
techniques include sample volume and cost. Analytical
method may influence plasma lipid and lipoprotein con-
centrations and characteristics, and it is not clear if these
potential differences have clinical implications (ie, identi-
fication of metabolic syndrome dyslipidemia or CVD risk
stratification). Therefore, the purpose of this investigation
was twofold: 1) to determine the influence of analytical
method (LAB 1 vs. LAB 2) on reported concentrations of
plasma lipids and lipoproteins, 2) to determine if there
are clinical implications for these differences (ie, on clini-
cal identification of the metabolic syndrome dyslipi-
demia, CVD risk stratification and classification of LDL
subclass phenotype).
Results and Discussion
As shown in Table 1, TG and HDL-C concentrations were
significantly higher (mean difference = 0.08 mmol/L and
0.10 mmol/L for TG and HDL-C, respectively), while total
cholesterol and LDL-C concentrations were significantly
lower according to LAB 2. Consequently, clinicians utiliz-
ing LAB 1 with these results would be less likely to catego-
rize individuals as meeting the ATP III criteria for TG
concentration, but more likely to categorize individuals as
meeting the ATP III criteria for HDL-C concentration. In
spite of these significant differences, the proportion of
individuals categorized as meeting both metabolic syn-
drome dyslipidemia criteria were similar (ie, 11 vs. 9 indi-
viduals from LABS 1 and 2, respectively). In addition, the
measurement differences between laboratories were con-
sistent as determined by the high rank order correlation of
variables (Table 1).
With respect to the number of circulating atherogenic par-
ticles in the plasma, the two laboratories differ slightly in
the type of information provided. LAB 1 measures apo B
concentration, and LAB 2 measures LDL particle number.
The two variables are not identical but should be corre-
lated, as each LDL particle carries one apoprotein B moi-
ety. However, apo B is also carried on very-low density
Table 1: Plasma Lipid and Lipoprotein Concentrations from Laboratories Utilizing Different Analytical Methods
Variable LAB 1 LAB 2 CorrelationB
Total Cholesterol, mmol/L 4.13 ± 0.08 3.82 ± 0.08A 0.92C
HDL-C, mmol/L 1.09 ± 0.03 1.19 ± 0.03A 0.91C
LDL-C, mmol/L* 2.53 ± 0.08 2.25 ± 0.05A 0.88C
Triglycerides, mmol/L 1.09 ± 0.06 1.17 ± 0.06A 0.96C
Number in sample meeting ATP III criteria
Triglycerides, n (%) 11 (10%) 14 (12%)D 0.78C
HDL-C, n (%) 70 (61%) 48 (42%)AD 0.60C
*calculated, Friedewald equation.
AP < 0.05 vs. LAB 1.
BSpearman's rho.
CSignificant correlation (P < 0.01).
DSignificant difference, Chi square (Trig: χ2 = 69.2, HDL-C: χ2 = 40.6; both P < 0.0001).Lipids in Health and Disease 2006, 5:3 http://www.lipidworld.com/content/5/1/3
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lipoproteins and intermediate density lipoproteins. These
findings (see Figure 1) indicate that the two measures are
highly correlated (r = 0.92, P < 0.01), even when analyzed
at different laboratories. Since it has been suggested that
apo B (or LDL particle number) be used in place of tradi-
tional lipid parameters (ie. TC, LDL-C, HDL-C, and trig-
lycerides) to assess CVD risk [8-10], the number of
individuals in our sample at increased risk according to
apo B concentrations (>120 mg/dl; 13) measured by LAB
1 as compared to LDL particle number (1300–1599
nmol/L; 14) measured by LAB 2 were compared. Using
laboratory-specific criteria, six individuals were identified
as being at increased risk based upon apo B concentra-
tions (LAB 1), while 20 individuals at increased risk based
upon LDL particle number (LAB 2). Mean 10-year Fram-
ingham risk scores [4] for these individuals identified at
increased risk based upon apo B or LDL particle number
were 3.8% (± 1.5) and 1.5% (± 0.5) at LABS 1 and 2,
respectively. The latter suggests that clinicians utilizing
LAB 1 would treat fewer individuals at higher CVD risk rel-
ative to LAB 1 if apo B was used in place of traditional
lipid parameters, as the Framingham risk score utilizes TC
and HDL-C concentrations. Conversely, utilizing LAB 2
would identify more individuals for intervention based
upon LDL particle number; those advocating for a more
aggressive approach for reduction of lipids and lipopro-
teins may view this as advantageous. Direct comparison of
the predictive value of LDL particle number vs. apo B con-
centration to CVD risk [15] and correlation with meta-
bolic syndrome features [15] suggest that LDL particle
number may be superior.
High correlations (r = 0.89) have been reported between
LDL particle sizes determined by GGE and NMR [15].
However, despite high correlations, differences may still
exist in categorization of individuals according to LDL
phenotype based upon LDL particle size measurement
when determined by different analytical methods. In our
comparison, LAB 2 was more likely to categorize individ-
uals as having the pattern B phenotype (see Figure 2); this
may in part be due to the use of the intermediate (AB)
phenotype classification by LAB 1 but not LAB 2. This may
have clinical significance in that an individual identified
as pattern B is at increased risk for CVD [5] and should be
evaluated for other features of the metabolic syndrome
[7]. Furthermore, the therapeutic treatment approach may
vary according to LDL phenotype classification [17],
which could be problematic if an individual is misclassi-
fied. Thus, follow-up testing of LDL particle size after
implementation of treatment would seem prudent to
ensure the appropriate treatment response.
Conclusion
Various laboratories offer plasma lipid and lipoprotein
assessment beyond the traditional lipid and lipoprotein
panel, such as lipoprotein characteristics (eg, particle size)
and number. These findings indicate that results may vary
according to the analytical method used, and that this var-
iability may have clinical implications for assessment of
CVD risk. Results from the two laboratories studied in this
investigation were significantly different; however, the
measurement difference was consistent (eg, if an individ-
ual's reported TG value was elevated according to LAB 1,
it was likely to be elevated according to LAB 2).
LDL Phenotype Classification According to Laboratories Uti- lizing Different Analytical Methods* Figure 2
LDL Phenotype Classification According to Laboratories Uti-
lizing Different Analytical Methods*. *Lab 1: Pattern B = LDL 
particle size < 22.0–25.74 nm; AB = 25.75–26.34 nm; Pattern 
A = 26.3–28.5 nm. Lab 2: Pattern B = LDL particle size ≤20.5 
nm; Pattern A = 20.6–22.0 nm. **Significant difference from 
LAB 1; Χ2 = 64.6, P < 0.0001.
Relationship of Apoprotein B Concentration (LAB 1) to LDL  Particle Number (LAB 2) Figure 1
Relationship of Apoprotein B Concentration (LAB 1) to LDL 
Particle Number (LAB 2).Lipids in Health and Disease 2006, 5:3 http://www.lipidworld.com/content/5/1/3
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Individuals with the metabolic syndrome dyslipidemia
risk determinants and with LDL subclass pattern B pheno-
type should be identified clinically, as they are at
increased risk for CVD. However, the laboratory method
used to analyze lipid and lipoprotein variables for CVD
risk stratification and diagnosis of the metabolic syn-
drome dyslipidemia appears to impact the proportion of
individuals identified to be "at-risk". Results from LAB 2
would categorize more individuals with the LDL pattern B
phenotype, as well as at increased CVD risk based upon
LDL particle number. Borderline results may warrant fol-
low-up testing to ensure the appropriateness of risk cate-
gorization as well as the treatment approach employed.
Thus, lipid and lipoprotein results from the two laborato-
ries studied were highly correlated (ie, r = 0.88–0.96), but
differ significantly in their categorization of individuals at
risk for CVD. These differences may lead to different clin-
ical treatment strategies.
Methods
Duplicate fasting plasma samples were obtained from 113
(70 men, 43 women) participants of a cross-sectional
research study. Participants were heterogeneous in terms
of age (range 18–70 years), activity level (V02 max range
19.7–82.0 ml/kg/min), and body weight (BMI range
17.8–39.9). Participants were excluded if they had a his-
tory of cardiovascular disease, diabetes, or other major
chronic disease. Physical characteristics (mean ± SEM) of
participants were as follows: age 31.1 (± 1.2) years; height
173.6 (± 1.0) cm; weight 79.1 (± 1.4) kg; BMI 26.2 (± 0.4)
kg/m2. All participants provided informed consent prior
to their participation in the investigation.
Plasma samples were sent to two commercial laboratories
specializing in plasma lipid and lipoprotein analyses.
Both laboratories are CLIA-certified (Centers for Medicare
and Medicaid Services Clinical Laboratory Improvement
Amendments). One laboratory (LAB 1) utilizes enzymatic
methods (TG, HDL-C, total cholesterol) plus gradient gel
electrophoresis (particle size, subclasses) [13,18] and the
other laboratory (LAB 2) utilizes nuclear magnetic reso-
nance spectroscopy [11]. With regard to analysis of the
number of circulating atherogenic particles, LAB 1 reports
apo B concentrations (mg/dl), while LAB 2 reports LDL
particle number (nmol/L). Concentrations of total choles-
terol, TG, HDL-C, LDL-C, LDL particle number and apo B,
and LDL subclass phenotype classification (Pattern A/B)
were compared between laboratories. In addition, the
proportion of individuals meeting ATP III dyslipidemia
criteria according to results reported by the two laborato-
ries was compared.
Spearman's rho rank order correlational analysis was used
to assess agreement in ranking of variables between LABS
1 and 2, and paired samples t-tests were used to determine
differences between laboratories. Chi square test of inde-
pendence analysis was used to determine if the number of
individuals classified as LDL pattern B phenotype and
those meeting ATP III criteria for TG and HDL-C differed
between laboratories (SPSS v. 12.0). Significance was
determined as P < 0.05. All data are expressed as Mean ±
SEM.
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